Date Title Description PDF
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download

Pages

35 / 44
Date Title Description PDF
26 Feb 2020 Annual Corporate Governance Report ROVI releases the 2019 Annual Corporate Governance Report Download
26 Feb 2020 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2019 annual report regarding remuneration of the members of the Board of Directors  Download

Pages

157 / 157
Date Title Description PDF
10 May 2018 Otros sobre negocio y situación financiera Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) Download
25 Apr 2018 Información sobre resultados ROVI releases the press release related to the 2018 first quarter financial results Download
25 Apr 2018 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting Download
25 Apr 2018 Información sobre resultados ROVI releases the 2018 first quarter results presentation Download
04 Apr 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the first quarter of 2018 Download

Pages

55 / 194